Full-Time

Global Publishing Manager

Regulatory Affairs

Confirmed live in the last 24 hours

Moderna

Moderna

5,001-10,000 employees

Develops mRNA-based medicines and therapies

Biotechnology
Healthcare

Senior

Cambridge, MA, USA

Expected to be in office 70% of the time with flexibility to work from home up to 30%.

Category
Legal
Risk & Compliance
Legal & Compliance
Requirements
  • Bachelor’s degree or equivalent.
  • At least 5 years of experience as a regulatory Publisher in a pharmaceutical company or CRO, with 2+ years in a management role.
  • Experience leading the submission of MAA, INDs, NDAs, BLAs, Master Files, etc., formatted according to international eCTD requirements.
  • Clinical report and global submission dossier publishing/compilation experience in the pharmaceutical or related industry.
  • Experience with electronic clinical document publishing standards/formats and global regulatory submission publishing standards/formats (e.g., eCTD, EU CTR).
  • Working knowledge of publishing tools (e.g., DXC, eCTD Xpress, Veeva), global submission validation tools, Document Management systems, Toolbox, HA electronic submission gateways, IRIS, CTIS, MS Office tools.
  • Familiarity with global Clinical and Regulatory HA requirements (e.g., FDA, ICH, EMA, MENA region, CH, MHRA).
  • Strong interpersonal and project management skills, with experience working in a complex, global cross-functional organization.
  • Highly motivated, organized, and detail-oriented team player.
  • Analytical thinker with excellent problem-solving skills and the ability to adapt to changing priorities and deadlines.
  • Ability to readily adjust to change in a fast-paced environment and multitask.
  • Positive attitude and ability to effectively collaborate with peers, stakeholders, and cross-functional colleagues in a global team environment.
  • Strong technical skills.
  • Strong communication and business writing skills.
  • Fluency in English.
Responsibilities
  • Compile, publish, and verify submission dossiers in accordance with international eCTD requirements.
  • Act as a team leader, providing direction, support, and mentorship to the publishing team.
  • Oversee the compilation, publishing, and verification of submission dossiers in accordance with international eCTD requirements and regulatory guidelines.
  • Lead and manage the submission of MAA, INDs, NDAs, BLAs, Master Files, and other regulatory documents.
  • Work closely with team members to compile documents, review hypertext links, ensure PDFs are submission ready, format tables and graphics, bookmark sections, and proof submissions according to internal standards.
  • Develop and implement new processes and procedures to enhance efficiency and accuracy during the submission process.
  • Collaborate with submissions management to build technically valid and high-quality dossiers.
  • Manage the submission of eCTD sequences through health authority gateways.
  • Perform quality control (QC) of documents published by team members to ensure compliance with applicable guidance documents.
  • Assist with the remediation of Word documents to ensure proper format and compliance.
  • Mentor and train team members to increase the quality across the team.
  • Participate in internal and external audits, maintaining compliance with department systems, e.g., project database, timesheets, training.
  • Contribute to the development of new publishing services and actively participate in department initiatives and process improvements.
  • Maintain a strong understanding of applicable regulatory guidelines and ensure the achievement of individual and team utilization targets.
  • Act as the primary point of contact for the team, providing regular updates to senior management on project status and any issues affecting quality, timelines, and adherence to contractual obligations.

Moderna focuses on developing medicines using messenger RNA (mRNA), which is a molecule that provides instructions for cells to produce proteins essential for various biological functions. Their approach involves creating a new class of medicines that leverage mRNA to potentially enhance the discovery, development, and manufacturing of drugs. Unlike traditional methods, which often rely on proteins or other biological materials, Moderna's use of mRNA allows for a more versatile and efficient way to create treatments. The company's goal is to improve patient outcomes by harnessing the power of mRNA to address a wide range of health issues.

Company Stage

Grant

Total Funding

$5.9B

Headquarters

Cambridge, Massachusetts

Founded

N/A

Growth & Insights
Headcount

6 month growth

3%

1 year growth

15%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • Moderna's expansion into combination vaccines and autoimmune therapies showcases its potential for diversified revenue streams and market leadership.
  • The company's continuous innovation and FDA approvals for updated COVID-19 vaccines highlight its resilience and adaptability in a rapidly changing market.
  • Moderna's educational initiatives, like the free mRNA course, position it as a thought leader and advocate for mRNA technology.

What critics are saying

  • The collapse in demand for COVID-19 vaccines could significantly impact Moderna's revenue and growth prospects.
  • Ongoing class action lawsuits alleging securities fraud could damage Moderna's reputation and financial stability.

What makes Moderna unique

  • Moderna is pioneering the use of mRNA technology to create a new class of medicines, setting it apart from traditional pharmaceutical companies.
  • The company's focus on mRNA as the 'software of life' allows for rapid development and manufacturing of vaccines and therapies, unlike conventional methods.
  • Moderna's ability to secure regulatory approvals for mRNA vaccines beyond COVID-19, such as for RSV, demonstrates its leadership in mRNA technology.

Help us improve and share your feedback! Did you find this helpful?